These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 34418266)

  • 1. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
    Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
    Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
    Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
    Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Stochastic Packaging of Cas Proteins into Exosomes].
    Ponomareva NI; Brezgin SA; Kostyusheva AP; Slatinskaya OV; Bayurova EO; Gordeychuk IV; Maksimov GV; Sokolova DV; Babaeva G; Khan II; Pokrovsky VS; Lukashev AS; Chulanov VP; Kostyushev DS
    Mol Biol (Mosk); 2024; 58(1):160-170. PubMed ID: 38943588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
    Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
    Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered Cas9 extracellular vesicles as a novel gene editing tool.
    Osteikoetxea X; Silva A; Lázaro-Ibáñez E; Salmond N; Shatnyeva O; Stein J; Schick J; Wren S; Lindgren J; Firth M; Madsen A; Mayr LM; Overman R; Davies R; Dekker N
    J Extracell Vesicles; 2022 May; 11(5):e12225. PubMed ID: 35585651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing.
    Dubey S; Chen Z; Jiang YJ; Talis A; Molotkov A; Ali A; Mintz A; Momen-Heravi F
    Theranostics; 2024; 14(7):2777-2793. PubMed ID: 38773978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles.
    Horodecka K; Düchler M
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
    Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
    J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment.
    Yan B; Liang Y
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
    Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
    Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras
    McAndrews KM; Xiao F; Chronopoulos A; LeBleu VS; Kugeratski FG; Kalluri R
    Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34282051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy.
    Ahmadi SE; Soleymani M; Shahriyary F; Amirzargar MR; Ofoghi M; Fattahi MD; Safa M
    Cancer Gene Ther; 2023 Jul; 30(7):936-954. PubMed ID: 36854897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
    Liu C; Zhang L; Liu H; Cheng K
    J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
    Xu Y; Liu R; Dai Z
    Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
    Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
    AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
    Cai W; Luo T; Mao L; Wang M
    Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in CRISPR/Cas9 Delivery Strategies.
    Yip BH
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.